Patent ID: 11884979
Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED
Field: Measurement (Instruments)
Classification: CPC C  G | IPC C  G

Claim 9:
10. A method for analyzing a sample, comprising:
(i) providing a biological sample obtained from a subject having, suspected of having, or being at risk for hereditary angioedema (HAE);
(ii) measuring the level of a RNA biomarker set, wherein the RNA biomarker set comprises a messenger RNA encoding mitochondrially-encoded cytochrome C oxidase III (MT-CO3);
(iii) identifying the subject as a subject at risk of HAE attack based on the level of the RNA biomarker set, an increase of the level of MT-CO3 of the subject from that of a control subject being indicative that the subject is at risk of HAE attack; and
(iv) administering to the subject identified as being at risk of HAE attack in step (iii) an effective amount of a therapeutic agent,
wherein the therapeutic agent is a plasma kallikrein (pKal) inhibitor, a bradykinin 2 receptor (B2R) inhibitor, and/or a Cl esterase inhibitor.